Corvus Pharmaceuticals Inc (CRVS) is a Healthcare · Biotechnology company listed on NASDAQ. Price $12.56 (+0.08%), Market cap $1.33B, 52-week low–high $3.47 ~ $25.52.
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1b/2 clinical trial for the treatment of peripheral T cell lymphoma, atopic dermatitis, hidradenitis suppurativa, autoimmune lymphoproliferative syndrome, and solid tumors monotherapy, and asthma, diseases. It also developing ciforadenant (CPI-444), an oral small molecule antagonist of the
Financial statements, price targets, institutional (13F) holdings and related news for Corvus Pharmaceuticals Inc are updated in real time on BlackAll Trade.
Corvus Pharmaceuticals Inc trades at $12.56 (+0.08%). Real-time quotes and charts are available on BlackAll Trade.
Corvus Pharmaceuticals Inc has a market cap of about $1.33B.
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation an